SCHEMBL2650170

SCHEMBL2650170

[CH](COc1ccccc1)Oc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.52
KCNA3 P22001 1/20 0.48
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RECQL P46063 1/20 0.43
ALOX15 P16050 1/20 0.41
LTA4H P09960 2/20 0.40
HTR1B P28222 2/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8038816 0.81 DRD2 (0.55) AOC3ALDH1A1DRD2DRD4DRD3
SCHEMBL10769434 0.79 AOC3 (0.50) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL8220198 0.79 CA4 (0.44) AOC3KCNA3LTA4HHTR1BLMNA
SCHEMBL6982008 0.79 AOC3 (0.50) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL3729055 0.78 AOC3 (0.42) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL8134399 0.78 KCNA3 (0.44) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL1024 0.77 KCNA3 (0.62) KCNA3HDAC3HDAC4HDAC1HDAC7
SCHEMBL6326458 0.77 AOC3 (0.59) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL1445312 0.77 AOC3 (0.58) AOC3KCNA3HDAC3HDAC4HDAC1
SCHEMBL419306 0.77 AOC3 (0.78) AOC3KCNA3HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3294718-B1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-04-29 EP disclosed
EP-3262026-B1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-03-18 EP disclosed
US-10428108-B2 Difluoroketamide derivatives HOFFMANN-LA ROCHE INC. (US) 2019-10-01 US disclosed
US-9980929-B2 Trifluoromethylpropanamide derivatives HOFFMAN-LA ROCHE INC. (US) 2018-05-29 US disclosed
EP-3294718-A1 NEW DIFLUOROKETAMIDE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-03-21 EP disclosed
US-20180057526-A1 NEW DIFLUOROKETAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-03-01 US disclosed
EP-3262026-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-01-03 EP disclosed
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-12-07 US disclosed
WO-2016180751-A1 NEW DIFLUOROKETAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-11-17 WO disclosed
WO-2016135070-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
CN-1520296-A Amino nicotinate derivatives as glucokinase (GLK) modulators 2004-08-11 CN disclosed
EP-1404335-A1 AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS Astrazeneca AB (SE) 2004-04-07 EP disclosed
WO-2003000267-A1 AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS ASTRAZENECA AB (SE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348257-A1 NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES PRMT7, GFRA3, PRMT5 AOC3 3287/4885KCNA3 150/4885HDAC3 20/4885
US-20180057526-A1 NEW DIFLUOROKETAMIDE DERIVATIVES PRMT9, CDK9, FLT3 AOC3 4349/4885KCNA3 378/4885HDAC3 1125/4885
US-10428108-B2 Difluoroketamide derivatives PRMT9, CDK9, FLT3 AOC3 3970/4885KCNA3 540/4885HDAC3 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.